Pricing pressure weighs on Amgen as Lumakras declines
Biotech firm Amgen says experimental obesity drug has promising durability | The Straits Times
Dr Reddy's to market three Amgen drugs in India - The Hindu BusinessLine
Amgen Gains FDA Approval for Parsabiv - Drug Discovery and Development
Johnson & Johnson: J&J sues Amgen over plan to sell drug similar to blockbuster Stelara, Health News, ET HealthWorld
LLY stock, Novo Nordisk to dominate Obesity despite Amgen entry (NYSE:LLY) | Seeking Alpha
Amgen to push latecomer obesity drug into midstage testing | pharmaphorum
J&J, Amgen, Regeneron Drugs Likely to Face Medicare Negotiation (1)
Bear-faced lie? Amgen retracts diabetes paper due to data manipulation
Amgen-partnered researchers treat diabetes in mice by silencing IL-2's inflammatory power | Fierce Biotech
Array BioPharma and Amgen Partner in Type 2 Diabetes| Amgen
AMGEN TO PRESENT NEW RESEARCH ACROSS SERIOUS INFLAMMATORY AND BONE DISEASES AT ACR 2022
New Drugs for the Treatment of Heart Failure | USC Journal
Amgen takes back three drugs from GSK - Clinical Professionals
Weight loss drugs power Novo Nordisk, Eli Lilly and Amgen shares
Tavneos Developer ChemoCentryx to be Acquired by Amgen for Almost $4 Billion - Xtalks
Amgen, Entera to Partner on Oral Drugs for Inflammatory Disease, Other "Serious" Illnesses
Amgen Stock: The Big Name You Need To Know In The Multibillion-Dollar Obesity Treatment Realm | Investor's Business Daily
How did Amgen Korea make key drugs reimbursable so quickly? < Pharma < Article - KBR
Reddy: Dr Reddy's Laboratories inks pact with Amgen to commercialise three drugs in India - The Economic Times
Amgen Has a Contender in the Weight-Loss Drug Wars - Bloomberg
Amgen balks over meeting to review cost of bone cancer drugs - STAT
Amgen - Wikipedia
Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs - MedCity News
